FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:941-942 October 6, 1994 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Chemotherapy for acute myeloid leukemia (AML) has long been the prototype for the intensive chemotherapy now widely used in the treatment of many cancers. It has been more than 25 years since Ellison et al. first showed that cytarabine could prolong survival substantially among patients with AML¹. Since that time, standard therapy, with induction and consolidation phases, has been synonymous with the most intense treatment possible for this once uniformly fatal disease.

In the past 10 years, the treatment that follows the induction of remission has intensified progressively, with encouraging results. For example, when performed during the first remission, . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Rowe, J. M., Tallman, M. S. (1997). Intensifying Induction Therapy in Acute Myeloid Leukemia: Has a New Standard of Care Emerged?. Blood 90: 2121-2126 [Full Text]